Theravance Biopharma Inc (TBPH) Hits New 52-Week High at $35.18
Theravance Biopharma Inc (NASDAQ:TBPH) shares reached a new 52-week high on Tuesday . The company traded as high as $35.18 and last traded at $34.82, with a volume of 99,597 shares trading hands. The stock had previously closed at $33.67.
A number of research analysts have weighed in on the stock. Leerink Swann reiterated a “buy” rating on shares of Theravance Biopharma in a research note on Saturday, June 4th. Zacks Investment Research upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research note on Tuesday, July 12th. Guggenheim assumed coverage on shares of Theravance Biopharma in a research note on Monday, June 20th. They issued a “buy” rating and a $30.00 target price on the stock. Evercore ISI assumed coverage on shares of Theravance Biopharma in a research note on Monday, August 29th. They issued a “buy” rating and a $41.00 target price on the stock. Finally, Bank of America Corp. cut shares of Theravance Biopharma from a “neutral” rating to an “underperform” rating in a research note on Wednesday, August 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $34.50.
The company’s 50 day moving average price is $28.35 and its 200 day moving average price is $23.03. The firm’s market cap is $1.67 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/theravance-biopharma-inc-tbph-hits-new-52-week-high-at-35-18.html
Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by $0.01. Theravance Biopharma had a negative net margin of 471.82% and a negative return on equity of 70.79%. On average, equities analysts predict that Theravance Biopharma Inc will post ($4.03) earnings per share for the current fiscal year.
In other Theravance Biopharma news, EVP Bradford J. Shafer sold 49,122 shares of the firm’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $27.46, for a total transaction of $1,348,890.12. Following the completion of the sale, the executive vice president now directly owns 241,686 shares in the company, valued at approximately $6,636,697.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Brett K. Haumann sold 4,491 shares of the firm’s stock in a transaction dated Thursday, August 25th. The shares were sold at an average price of $27.99, for a total transaction of $125,703.09. Following the sale, the senior vice president now owns 188,293 shares of the company’s stock, valued at $5,270,321.07. The disclosure for this sale can be found here. Company insiders own 4.70% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in TBPH. Teacher Retirement System of Texas raised its stake in Theravance Biopharma by 40.2% in the second quarter. Teacher Retirement System of Texas now owns 4,887 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 1,401 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Theravance Biopharma by 3.3% in the second quarter. PNC Financial Services Group Inc. now owns 5,992 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 192 shares in the last quarter. Bellevue Group AG purchased a new stake in Theravance Biopharma during the first quarter worth $215,000. Paloma Partners Management Co purchased a new stake in Theravance Biopharma during the second quarter worth $255,000. Finally, OMERS ADMINISTRATION Corp raised its stake in Theravance Biopharma by 21.2% in the first quarter. OMERS ADMINISTRATION Corp now owns 13,828 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 2,419 shares in the last quarter. Institutional investors and hedge funds own 69.89% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.